Author: "Aurélie Du Thanh" / Topic: business.industry - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Aurélie Du Thanh"' showing total 68 results

Start Over Author "Aurélie Du Thanh" Topic business.industry

68 results on '"Aurélie Du Thanh"'

1. Lethal anaplastic large-cell lymphoma occurring in a patient treated with dupilumab

Author: Olivier Dereure, Valentin Gustave, Aurélie Du-Thanh, DIAMANT-BERGER, Valérie, Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier], and Université de Montpellier (UM)
Subjects: medicine.medical_specialty, CD30, [SDV]Life Sciences [q-bio], CTCL, cutaneous T-cell lymphoma, Case Report, Dermatology, dupilumab, hemic and lymphatic diseases, medicine, Anaplastic large-cell lymphoma, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, atopic dermatitis, business.industry, Cutaneous T-cell lymphoma, Large cell anaplastic lymphoma, AD - Atopic dermatitis, Atopic dermatitis, AD, atopic dermatitis, large-cell anaplastic lymphoma, systemic, medicine.disease, Dupilumab, Lymphoma, [SDV] Life Sciences [q-bio], RL1-803, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: The occurrence or the worsening of cutaneous T-cell lymphoma (CTCL) during or after a treatment with dupilumab has recently been reported in a limited number of patients including a small series of 7 patients, of whom 4 had been previously diagnosed with atopic dermatitis (AD).1 We hereby describe a previously unreported observation of systemic CD30+ lymphoproliferation occurring during treatment with dupilumab, adding to the literature of new-onset cutaneous lymphomas associated with dupilumab therapy.
Published: 2021
Full Text: View/download PDF

2. COVID‐19 as a trigger of acute attacks in people with hereditary angioedema

Author: Olivier Fain, Aude Belbézier, Chloe McAvoy, Mélanie Arnaud, D. Gobert, Aurélie Du-Thanh, Isabelle Boccon-Gibod, Laurence Bouillet, Julien Lupo, David Launay, Fabien Pelletier, Centre Hospitalier Universitaire [Grenoble] (CHU), Centre de référence des angioedèmes à kinines (CREAK), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Claude Huriez [Lille], CHU Lille, Université de Lille, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Grenoble Alpes (UGA), Centre de référence national des angiœdèmes (CREAK), CHU Grenoble-Université Grenoble Alpes (UGA), and BONIZEC, Sandrine
Subjects: 0301 basic medicine, Adult, Male, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), [SDV]Life Sciences [q-bio], Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, angiotensin‐converting enzyme inhibitor, 03 medical and health sciences, 0302 clinical medicine, COVID‐19, Research Letter, Immunology and Allergy, Medicine, Humans, In patient, Registries, ComputingMilieux_MISCELLANEOUS, Aged, Aged, 80 and over, business.industry, SARS-CoV-2, HAE, Angioedemas, Hereditary, COVID-19, Middle Aged, medicine.disease, Research Letters, hereditary angioedema, 3. Good health, [SDV] Life Sciences [q-bio], Convalescent phase, 030104 developmental biology, 030228 respiratory system, Hereditary angioedema, Female, business
Abstract: Acute attacks could occur during the convalescent phase of COVID-19 illness, more commonly in patients with a history of frequent attacks. However it is unclear whether the acute attacks during the convalescent phase are specifically triggered by COVID-19 or not.
Published: 2021
Full Text: View/download PDF

3. Allergic contact dermatitis in response to cetearyl glucoside from a topical drug

Author: Amandine Baudy, Nadia Raison-Peyron, Olivier Dereure, and Aurélie Du-Thanh
Subjects: medicine.medical_specialty, Cetearyl glucoside, Topical drug, business.industry, Administration, Topical, Dermatology, Cosmetics, Hand Dermatoses, Patch Tests, medicine.disease, Surface-Active Agents, Dermatitis, Allergic Contact, medicine, Immunology and Allergy, Humans, Glycolipids, business, Allergic contact dermatitis
Published: 2021

4. Rare cutaneous toxicity of immune checkpoint inhibitors: A case of durvalumab-induced dermatomyositis

Author: Alexandre Thibault Jacques Maria, Cyrille Coustal, Eric Assenat, Aurélie Du Thanh, François Roubille, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Saint Eloi (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), MORNET, Dominique, CHU Saint-Eloi, and Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Subjects: 0303 health sciences, Cancer Research, Durvalumab, business.industry, Immune checkpoint inhibitors, [SDV]Life Sciences [q-bio], Cutaneous toxicity, Dermatomyositis, medicine.disease, Myasthenia gravis, 3. Good health, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, Cancer research, business, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology
Abstract: International audience
Published: 2021
Full Text: View/download PDF

5. Outcome of pretransplant melanoma after solid organ transplantation: an observational study

Author: Denis Jullien, Jacques Dantal, Céleste Lebbé, Aurélie Du Thanh, Julie Delyon, Christophe Legendre, Evelyne Decullier, Marion Patras, Jean Kanitakis, Manal Mazloum, Emmanuel Morelon, Feriel Boukari, and Emilie Ducroux
Subjects: Oncology, Male, Transplantation, medicine.medical_specialty, Skin Neoplasms, business.industry, Melanoma, Organ Transplantation, Sequence Analysis, DNA, medicine.disease, Kidney Transplantation, Organ transplantation, Stage ib, Internal medicine, medicine, Humans, Observational study, Stage (cooking), Solid organ transplantation, business, Melanoma diagnosis
Abstract: Background The number of patients with a history of melanoma who are waiting a solid organ transplantation (SOT) is increasing. Few recommendations exist on the timing to transplantation after melanoma diagnosis. The aim of this study was to assess the melanoma recurrence-free survival after pretransplant melanoma (PTM). Methods We conducted a multicenter ambispective observational study. Organ transplant recipients (OTR) with a history of PTM and complete AJCC staging were included. Results Thirty-seven patients (predominantly men with a renal allograft) were included. Five melanomas were in situ, 21 stage IA, 4 stage IB, 5 stage II and 2 stage IIIB. The median post-transplantation follow-up time was 4 years. 62% of patients were followed more than 2 years. Recurrence-free survival since melanoma reached 89.9%, but varied significantly according to AJCC staging (p=0.0129). Three patients presented a recurrence. Conclusion Despite the rather limited sample size and a wide range of follow-up, our findings concerning the recurrence-free survival appear reassuring for in situ and stage IA PTM; accordingly we suggest that a waiting time to transplantation is not mandatory in patients with in situ or stage IA PTM, especially whenever SOT I s urgently needed. Caution is however needed for patients with higher stage.
Published: 2021

6. Omalizumab in cold urticaria in children: Retrospective case series of 13 patients, review of the literature

Author: C. Briand, Angèle Soria, Aurélie Du-Thanh, Delphine Staumont-Sallé, F. Castelain Lakkis, Christine Chiaverini, B. Sterling, Florence Tetart, Nadia Raison-Peyron, and F. Boralevi
Subjects: Series (stratigraphy), medicine.medical_specialty, Urticaria, business.industry, Diagnostic Tests, Routine, Dermatology, Omalizumab, Cold urticaria, medicine.disease, Treatment Outcome, Anti-Allergic Agents, Chronic Disease, Medicine, Humans, business, Child, medicine.drug, Retrospective Studies
Published: 2021

7. Toward a holistic management of skin and joint disorders in PsA patients

Author: Camille Roubille, Céline Girard, Jacques Morel, Aurélie Du Thanh, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Subjects: 030203 arthritis & rheumatology, medicine.medical_specialty, business.industry, [SDV]Life Sciences [q-bio], Arthritis, Psoriatic, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Rheumatology, medicine, Humans, Holistic management, Joint disorder, Pharmacology (medical), Joint Diseases, Intensive care medicine, business, ComputingMilieux_MISCELLANEOUS, Skin
Abstract: International audience
Published: 2021
Full Text: View/download PDF

8. COVID-19 in HAE patients: a prospective study

Author: Olivier Fain, D. Gobert, Isabelle Boccon-Gibod, Fabien Pelletier, Mélanie Arnaud, Aude Belbézier, Laurence Bouillet, Julien Lupo, Aurélie Du-Thanh, and Chloe McAvoy
Subjects: medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Internal medicine, Medicine, business, Prospective cohort study
Published: 2020
Full Text: View/download PDF

9. Angiœdèmes par déficit acquis en C1-inhibiteur : recommandations du CREAK pour le diagnostic et la prise en charge

Author: Gaëlle Hardy, Virginie Panayotopoulos, F. Defendi, D. Launay, Aurélie Du-Thanh, Laurence Bouillet, G. Armengol, D. Gobert, Isabelle Boccon-Gibod, Pierre-Yves Jeandel, Nicolas Javaud, Olivier Fain, Fabien Pelletier, Paul Coppo, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de référence national des angiœdèmes (CREAK), CHU Grenoble-Université Grenoble Alpes (UGA), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Rouen, Normandie Université (NU), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nice (CHU Nice), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Lille, and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: medicine.medical_specialty, Bradykinine, [SDV]Life Sciences [q-bio], Bradykinin, C1-inhibitor, 030204 cardiovascular system & hematology, Angiœdème acquis, Thrombophilia, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, immune system diseases, Icatibant, C1-inhibiteur, Internal Medicine, medicine, Déficit acquis en C1-inhibiteur, 030212 general & internal medicine, Danazol, Angioedema, Angiœdème bradykinique, business.industry, Acquired C1-inhibitor deficiency, Gastroenterology, Kallikrein, medicine.disease, Dermatology, 3. Good health, chemistry, Rituximab, medicine.symptom, business, Tranexamic acid, Bradykininin angioedema, medicine.drug
Abstract: International audience; Acquired angioedema with C1-inhibitor deficiency is a rare and peculiar entity belonging to the spectrum of bradykinin angioedemas. It usually occurs in subjects over 60 years old, and is mostly associated with a B-cell lymphoid hemopathy or a monoclonal gammopathy.The diagnosis relies on at least one angioedema episode, lasting more than 24 h, and on the decrease of functional C1-inhibitor. Low C1q is observed in 90% of patients, and an anti C1-inhibitor antibody is found in 50% of patients.The treatment of severe attacks relies on icatibant or C1-inhibitor perfusions. Long term prophylaxis in patients with frequent attacks requires treatment of the associated hemopathy if so. In case of idiopathic angioedema, tranexamic acid and danazol may be used, provided that there is-no thrombophilia; as well as rituximab as second-line treatment. Inhibitors of kallikrein still need to be evaluated in this therapeutic indication.; Les angiœdèmes par déficit acquis en C1-inhibiteur représentent une entité rare au sein des angiœdèmes bradykiniques. Ils diffèrent des formes héréditaires essentiellement par le terrain, car ils surviennent chez des sujets âgés de 60 ans en moyenne, et sont, le plus souvent, associés à une hémopathie lymphoïde B de bas grade ou à une gammapathie monoclonale.Leur diagnostic repose sur la survenue d'au moins un épisode d'angiœdème durant plus de 24 heures et sur la diminution de C1-inhibiteur fonctionnel. Une baisse du C1q est présente dans 90 % des cas et un anticorps anti C1-inhibiteur chez 50 % des patients.Le traitement des crises sévères repose sur l'icatibant ou l'administration de C1-inhibiteur. Le traitement préventif, indiqué en cas de crises fréquentes, nécessite le traitement de l'hémopathie identifiée. En l'absence de pathologie associée, l'acide tranexamique ou le danazol sont des options à envisager en l'absence de facteur de risque de thrombose, et le rituximab peut être proposé en cas d'échec. La place des inhibiteurs de la kallicréine sera à définir dans cette indication.
Published: 2020
Full Text: View/download PDF

10. Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis

Author: Aurélie Du-Thanh, Audrey Nosbaum, Angèle Soria, Fatma Jendoubi, M-C Ferrier le Bouedec, Nadia Raison-Peyron, A. Valois, Marie Jachiet, Sébastien Barbarot, Audrey Lasek, P. Marcant, R. Merhi, P. Balayé, Delphine Staumont-Sallé, and Florence Tetart
Subjects: Moderate to severe, medicine.medical_specialty, business.industry, Eczema, Hypereosinophilia, Dermatology, Atopic dermatitis, medicine.disease, Antibodies, Monoclonal, Humanized, Dupilumab, Severity of Illness Index, Dermatitis, Atopic, Infectious Diseases, Treatment Outcome, Eosinophilia, Medicine, Humans, In patient, medicine.symptom, business
Published: 2020

11. Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib and trametinib combination: two cases

Author: Quentin Samaran, Olivier Dereure, Sarah Theret, O. Becquart, C. Lesage, Aurélie Du Thanh, Dorian Belakebi, Céline Girard, Bernard Guillot, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
Subjects: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Targeted therapy, 0302 clinical medicine, Oximes, Melanoma, Trametinib, MESH: Aged, MESH: Middle Aged, Imidazoles, Middle Aged, MESH: Oximes, 3. Good health, 030220 oncology & carcinogenesis, MESH: Imidazoles, medicine.drug, medicine.medical_specialty, Combination therapy, Pyridones, MESH: Melanoma, MESH: Pyrimidinones, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, Pyrimidinones, Lymphohistiocytosis, Hemophagocytic, 03 medical and health sciences, Internal medicine, MESH: Pyridones, MESH: Lymphohistiocytosis, Hemophagocytic, medicine, Humans, Aged, Hemophagocytic lymphohistiocytosis, Cytopenia, MESH: Humans, business.industry, MESH: Skin Neoplasms, Dabrafenib, Immunotherapy, medicine.disease, MESH: Male, 030104 developmental biology, Concomitant, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; Hemophagocytic lymphohistiocytosis (HLH) has been only rarely reported in patients with BRAF-mutated advanced melanoma treated with targeted therapies and never with first-line dabrafenib/trametinib combination thus far. Two patients treated with first-line dabrafenib and trametinib combination therapy for metastatic melanoma presented with sudden occurrence of fever, cytopenia, rhabdomyolysis, hepatic cytolysis, hypertriglyceridemia and very high ferritin levels after few weeks of treatment, associated with concomitant epstein-barr virus (EBV) reactivation in one patient. In both cases, drug-induced HLH was primarily considered owing to a high H-score and the absence of other etiology. Patients rapidly improved after treatment discontinuation associated with oral steroids in one patient and did not relapse after subsequent treatment resumption with a concurrent anti-BRAF/anti-MEK combination. In metastatic melanoma HLH may occur either spontaneously in the absence of any treatment as a paraneoplastic condition, related to an intercurrent infection or drug-induced mainly with various immunotherapy or with dabrafenib and trametinib following immunotherapy. However, such observations are scarce and these are the first cases of HLH occurring during first-line treatment with dabrafenib and trametinib in advanced melanoma to our knowledge. Pathomechanisms remain to be elucidated since triggering factors may encompass the treatment itself but also other significant actors including viral reactivation along with the underlying disease. The liability of treatment should be considered in cases of HLH occurring in patients with advanced melanoma successfully treated with a combined targeted therapy. A rechallenge with a concurrent anti-BRAF/anti-MEK can be proposed in this setting.
Published: 2020
Full Text: View/download PDF

12. Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases

Author: Dan Lipsker, Olivier Dereure, Nicolas Terrail, B. Bergeret, M. Dandurand, Valerie Reymann, Didier Bessis, Aurélie Du-Thanh, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and CHU Strasbourg
Subjects: medicine.medical_specialty, Best Overall Response, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Refractory, MESH: Lenalidomide, medicine, Lupus Erythematosus, Cutaneous, Humans, Lenalidomide, ComputingMilieux_MISCELLANEOUS, MESH: Treatment Outcome, 030203 arthritis & rheumatology, MESH: Humans, business.industry, Low dose, MESH: Thalidomide, MESH: Lupus Erythematosus, Cutaneous, University hospital, Institutional review board, 3. Good health, Thalidomide, Infectious Diseases, Treatment Outcome, Relative risk, Cutaneous Lupus Erythematosus, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.drug
Abstract: Lenalidomide (LND), a synthetic thalidomide analog mainly used in haematological malignancies has proved efficient and well-tolerated in small case series of refractory Cutaneous Lupus Erythematosus (CLE). A retrospective survey of CLE patients treated with low-dose LND in three institutional Departments of Dermatology was conducted to further assess the benefit/risk ratio of this molecule in this setting (Institutional Review Board for ethical issues of University Hospital of Montpellier 2018_IRB-MTP_11-01). Primary endpoints were best overall response (BOR) obtained with initial dosage or after dose adjustment and time to achieve BOR.
Published: 2020
Full Text: View/download PDF

13. Definition, aims, and implementation of GA [sup] 2 LEN/HAEi Angioedema Centers of Reference and Excellence

Author: Kemal Özyurt, Teresa Caballero, Aharon Kessel, Andrew J. MacGinnitie, Solange Oliveira Rodrigues Valle, Anthony J. Castaldo, Markus Magerl, Regis A. Campos, Adam Reich, Heike Röckmann-Helmbach, R. Y. Meshkova, Mario Sánchez-Borges, Richard G. Gower, Anna Zalewska-Janowska, Daria Fomina, Célia Costa, Allen P. Kaplan, Marc A. Riedl, Naoko Inomata, Avner Reshef, Alejandro Malbrán, Aurélie Du-Thanh, N. Prior, Hilary Longhurst, Margarida Gonçalo, Kiran Godse, Rosana Câmara Agondi, Andreas Kleinheinz, Inmaculada Martinez-Saguer, Mona Al-Ahmad, Thilo Jakob, Luis Felipe Ensina, José Ignacio Larco Sousa, Anna Tagka, Chikako Nishigori, Nicola Wagner, Hye Ryun Kang, Michael Makris, Nicholas Brodszki, Ricardo Dario Zwiener, Jan Nicolay, Alicja Kasperska-Zając, Iris V Medina, Ignacio J. Ansotegui, Marcin Stobiecki, Alejandro Berardi, Danny M. Cohn, Claudio A S Parisi, Angèle Soria, Torsten Zuberbier, Dario O. Josviack, E Serra-Baldrich, Jonathan A. Bernstein, Anette Bygum, Isao Ohsawa, Henriette Farkas, Iman Nasr, Thomas Buttgereit, Jonathan Peter, Carsten Bindslev-Jensen, Paulo Ricardo Criado, Wolfgang Pfützner, Natalia Fili, Silvia Mariel Ferrucci, Petra Staubach, Peter Schmid-Grendelmeier, M. Gotua, Marcus Maurer, Jose Fabiani, Gordon Sussman, A. Marsland, Konrad Bork, Andrea Zanichelli, Simon Francis Thomsen, Isabelle Boccon-Gibod, Mauro Cancian, German D. Ramon, Zuotao Zhao, Nikolaos G. Papadopoulos, Martijn B. A. van Doorn, Andrea Bauer, Kanokvalai Kulthanan, Claudio Fantini, Henrik Balle Boysen, Lilian Varga, Dorota Krasowska, Ana Giménez-Arnau, Werner Aberer, Ivan Cherrez-Ojeda, Roberta F. Criado, Constance H. Katelaris, Martin Metz, Riccardo Asero, Mitja Košnik, Stephen Betschel, M Sendhil Kumaran, Sigurd Broesby-Olsen, Moshe Ben-Shoshan, Rand Arnaout, Regina Treudler, Laurence Bouillet, Natalia Ilina, Maryam Ali Al-Nesf, Emek Kocatürk, Emel Aygören-Pürsün, William R. Lumry, Guillermo Guidos-Fogelbach, Yuxiang Zhi, Mark Gompels, Andac Salman, Christina Weber-Chrysochoou, Michihiro Hide, Young Min Ye, Aslı Gelincik, William B Smith, Timothy J. Craig, Bruce Ritchie, Daniel O. Vázquez, Mojca Bizjak, Atsushi Fukunaga, Ragıp Ertaş, Urs C. Steiner, Faradiba Sarquis Serpa, Farrukh R. Sheikh, Michael Rudenko, Paula J. Busse, Luisa Karla de Paula Arruda, Liangchun Wang, Todor A. Popov, Anete Sevciovic Grumach, Joachim Dissemond, Dorottya Csuka, Ignasi Figueras-Nart, Aleena Banerji, Tıp Fakültesi, Kemal Özyurt / 0000-0002-6913-8310, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Maurer, Marcus, Werner, Aberer, Agondi, Rosana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Aygoeren-Puersue, Emel, Banerji, Aleena, Bauer, Andrea, Ben-Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A, Betschel, Stephen, Bindslev-Jensen, Carsten, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby-Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, Regis A., Cancian, Mauro, Cherrez-Ojeda, Ivan, Cohn, Danny M., Costa, Celia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du-Thanh, Aurelie, Ensina, Luis Felipe, Ertaş, Ragıp, Fabiani, Jose E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Aslı, Gimenez-Arnau, Ana, Godse, Kiran, Gompels, Mark, Goncalo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S, Guidos-Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye-Ryun, Kaplan, Allen, Kasperska-Zajac, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, Jose Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbran, Alejandro, Marsland, Alexander, Martinez-Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako V., Nishigori, Chikako, Ohsawa, Isao, Özyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pfuetzner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, Rockmann-Helmbach, Heike, Rudenko, Michael, Salman, Andaç, Sanchez-Borges, Mario, Schmid-Grendelmeier, Peter, Serpa, Faradiba S., Serra-Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Angele, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, van Doorn, Martijn, Varga, Lilian, Vazquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber-Chrysochoou, Christina, Ye, Young-Min, Zalewska-Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., Castaldo, Anthony, and School of Medicine
Subjects: medicine.medical_specialty, Edema angioneuròtic, Urticaria, media_common.quotation_subject, Immunology, education, GA2LEN, Angioedema, Center, Excellence, Management, urticaria, centres of reference and excelence, immune system diseases, center, medicine, Immunology and Allergy, Center (algebra and category theory), Angioneurotic edema, skin and connective tissue diseases, media_common, udc:616.1, business.industry, angioedema, humanities, referenčni centri odličnosti, Medicine, Allergy, Family medicine, excellence, medicine.symptom, business, Global Allergy and Asthma European Network, Urticària, management
Abstract: This document summarizes the aims of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence (ACAREs) and elaborates the requirements that ACAREs must fulfill to become certified. It also provides (see Appendix S1) background information on GA2LEN and HAEi, including HAEi member organizations and regional patient advocates, on why we need an Angioedema Center of Reference and Excellence (ACARE) program and network, and on the accreditation and certification process, governance and funding, and on the interaction with other GA2LEN networks of centers of reference and excellence. The protocols, aims, requirements, and provisions related to becoming a certified CARE are based on (a) the experience of the GA2LEN UCARE network and (b) input from angioedema patients, general practitioners, and angioedema specialists.
Published: 2020
Full Text: View/download PDF

14. Low- vs. Middle-dose Total Skin Electron Beam Therapy for Mycosis Fungoides: An Efficiency-based Retrospective Survey of Skin Response

Author: Aurélie Du-Thanh, M. Charissoux, Christine Kerr, Annelies Taverniers, Olivier Dereure, Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), CRLCC Val d'Aurelle - Paul Lamarque, and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Subjects: Adult, Male, medicine.medical_specialty, Skin Neoplasms, [SDV]Life Sciences [q-bio], total skin electron beam therapy, Electrons, Dermatology, middle dose, Gastroenterology, Disease-Free Survival, 030207 dermatology & venereal diseases, 03 medical and health sciences, Total skin electron beam therapy, 0302 clinical medicine, Retrospective survey, Internal medicine, medicine, Humans, Adverse effect, ComputingMilieux_MISCELLANEOUS, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Mycosis fungoides, mycosis fungoides, business.industry, Skin response, Significant difference, Low dose, Radiotherapy Dosage, General Medicine, Middle Aged, medicine.disease, 3. Good health, Treatment Outcome, low dose, Median time, RL1-803, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
Abstract: Optimal doses of total skin electron beam therapy for mycosis fungoides remain to be established. Clinical efficiency and adverse effects of middle-dose (25 Gy) vs. low-dose (10-12 Gy) total skin electron beam therapy were retrospectively compared in a series of 14 and 12 mycosis fungoides, respectively. Overall skin response rate was 96.2% (92.9% middle-dose and 100% low-dose; not significant (NS)). Overall complete and partial skin response rates were 57.7% (42.9% middle-dose and 75% low-dose; NS) and 38.5% (50% middle-dose and 25% low-dose; NS), respectively. All responding patients relapsed after an overall median time of 5 months (7 months middle-dose vs. 4 months low-dose; p = 0.164, NS). Tolerance was equally fair in both groups, with only grade 1 and 2 adverse events observed in 100% vs. 66.7% of patients in middle-dose and low-dose groups (NS). Although no significant difference was observed, middle-dose protocol may be recommended owing to a longer relapse-free survival for a similar tolerance.
Published: 2019
Full Text: View/download PDF

15. Are Adverse Events Attributed to Essure Associated With Nickel Sensitization?

Author: Sarah Francini, Patrice Crochet, Claire Duflos, Clara Compan, Nadia Raison-Peyron, Hélène Perrochia, and Aurélie Du-Thanh
Subjects: Adult, medicine.medical_specialty, Metrorrhagia, Sterilization, Tubal, medicine.medical_treatment, Eczema, Dermatology, Hysteroscopy, Pelvic Pain, Skin Diseases, 030207 dermatology & venereal diseases, 03 medical and health sciences, Salpingectomy, 0302 clinical medicine, Nickel, Oximes, medicine, Immunology and Allergy, Humans, Medical history, Hypersensitivity, Delayed, 030212 general & internal medicine, Adverse effect, Sensitization, Device Removal, Fallopian Tubes, Fatigue, Hysteroscopic sterilization, business.industry, Headache, Prostheses and Implants, Allergens, Middle Aged, Patch Tests, medicine.disease, Arthralgia, medicine.anatomical_structure, Dyspareunia, Essure, Delayed hypersensitivity, Female, Laparoscopy, business, Contact dermatitis
Abstract: Background Essure is an effective method for hysteroscopic sterilization. Reports of adverse effects, the underlying mechanisms of which are unknown, have increased in recent years. Objective The aim of the study was to determine whether there is a relationship between adverse events attributed to Essure and nickel sensitization. Methods Patients presenting alleged adverse reactions to Essure were referred for nickel patch testing before removal. Data regarding medical history of nickel sensitization and symptoms attributed to Essure were collected. Dimethylglyoxime spot tests were performed on the explanted Essure. There was a follow-up at 3 months to evaluate whether there is improvement of the symptoms after Essure removal. Conclusions Nickel sensitization via the classic delayed hypersensitivity pathway did not seem to be responsible for adverse events attributed to Essure. Among systemic symptoms reported, extracutaneous symptoms had the highest prevalence. Systemic contact dermatitis to nickel could not be ruled out in one case.
Published: 2020

16. Itchy Erythematous Plaques after Scuba Diving: A Quiz

Author: Emilie Schwob, Aurélie Du-Thanh, Nicolas Marmion, Olivier Dereure, Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Michel-Avella, Amandine
Subjects: Adult, medicine.medical_specialty, Cutis marmorata, [SDV]Life Sciences [q-bio], Diving, patent foramen ovale, Dermatology, decompression sickness, Skin Diseases, Decompression sickness, InformationSystems_MODELSANDPRINCIPLES, Abdomen, Erythematous plaque, ComputingMilieux_COMPUTERSANDEDUCATION, lcsh:Dermatology, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Hardware_MEMORYSTRUCTURES, cutis marmorata, business.industry, Pruritus, ComputingMilieux_PERSONALCOMPUTING, General Medicine, lcsh:RL1-803, medicine.disease, Scuba diving, [SDV] Life Sciences [q-bio], Erythema, Patent foramen ovale, Female, medicine.symptom, business
Abstract: is missing (Quiz)
Published: 2020
Full Text: View/download PDF

17. No evidence for viral transcripts in dermatofibrosarcoma protuberans

Author: Aurélie Du-Thanh, Philippe Pérot, Vincent Foulongne, Olivier Dereure, Marc Eloit, Bernard Guillot, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Biologie des Infections - Biology of Infection, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: 0303 health sciences, Skin Neoplasms, business.industry, Biopsy, [SDV]Life Sciences [q-bio], Dermatofibrosarcoma, Endogenous Retroviruses, Dermatology, medicine.disease, Genomic Instability, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Text mining, 030220 oncology & carcinogenesis, Cancer research, Dermatofibrosarcoma protuberans, medicine, Humans, RNA, Viral, business, Skin, 030304 developmental biology
Abstract: International audience; Research Letter
Published: 2019
Full Text: View/download PDF

18. Is photodynamic therapy a relevant therapeutic option in refractory benign familial pemphigus (Hailey–Hailey disease)? A series of eight patients

Author: Olivier Dereure, Maha Alsahli, Aurélie Du Thanh, Céline Girard, A. Debu, Didier Bessis, Bernard Guillot, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
Subjects: Adult, Male, medicine.medical_specialty, Light, Pemphigus, Benign Familial, medicine.medical_treatment, education, Pain, Photodynamic therapy, Dermatology, Disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Refractory, Quality of life, Methyl aminolevulinate, medicine, Multiple treatments, Humans, Benign familial pemphigus, Aged, Photosensitizing Agents, business.industry, Drug Tolerance, Middle Aged, medicine.disease, Levulinic Acids, Hailey–Hailey disease, 3. Good health, Treatment Outcome, Photochemotherapy, methyl-aminolevulinate, photodynamic therapy, 030220 oncology & carcinogenesis, Quality of Life, Female, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Follow-Up Studies, medicine.drug
Abstract: Treatment of benign familial pemphigus or Hailey-Hailey disease (HHD), a rare inherited condition associated with a significant impairment of quality of life, is often challenging and disappointing with frequent relapses and infectious complications. Topical photodynamic therapy (PDT) may offer new perspectives in this difficult setting.Eight patients with long-lasting HHD lesions refractory to multiple treatments were treated on at least one involved site with PDT using methyl-amino levulinate with a standardized protocol of three sessions of irradiation separated by 3-week intervals.A complete or partial clearing was achieved in all treated areas, and the result was satisfactorily maintained in all cases after a follow-up period ranging from 3 to 36 months. Results were of higher quality in non-inguinal areas. Tolerance was overall acceptable with local pain during and shortly after irradiation being the main limiting factor.Our series, although limited in size, emphasizes the interest of PDT in this difficult condition even though results may be incomplete. Treatment-related pain can be adequately managed by prior analgesics, cooling with sprayed water and local tumescent anesthesia. Overall, PDT appears as a relevant option in refractory HHD management with a favorable benefit/risk ratio.
Published: 2017
Full Text: View/download PDF

19. Efficacy of C1 inhibitor concentrate in hereditary angioedema with C1 inhibitor deficiency

Author: Aurélie Du Thanh, Laurence Bouillet, Isabelle Boccon-Gibod, Olivier Fain, and Aude Belbézier
Subjects: 0301 basic medicine, Pulmonary and Respiratory Medicine, medicine.medical_specialty, biology, C1 inhibitor deficiency, business.industry, Immunology, medicine.disease, Dermatology, C1-inhibitor, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030228 respiratory system, Hereditary angioedema, Cohort, medicine, biology.protein, Immunology and Allergy, business
Published: 2018
Full Text: View/download PDF

20. Occupational fixed drug eruption with ipe wood

Author: Quentin Landry, Nadia Raison-Peyron, Olivier Dereure, Aurélie Du-Thanh, Jean-Luc Bourrain, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
Subjects: Adult, Male, fixed drug eruption, naphthoquinone, Dermatology, Tabebuia, ipe, 030207 dermatology & venereal diseases, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Hyperpigmentation, case report, Humans, Immunology and Allergy, Medicine, exotic wood, occupational, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Traditional medicine, biology, business.industry, Pruritus, Construction Industry, medicine.disease, biology.organism_classification, Wood, Naphthoquinone, Drug eruption, sawdust, Dermatitis, Occupational, chemistry, Erythema, visual_art, visual_art.visual_art_medium, Sawdust, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience
Published: 2018
Full Text: View/download PDF

21. Monoclonal antibodies: also for dermatologists!

Author: Bernard Guillot, Aurélie Du-Thanh, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), and Salvy-Córdoba, Nathalie
Subjects: medicine.medical_specialty, [SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Therapeutic monoclonal antibodies, medicine.drug_class, omalizumab and lanadelumab, Lanadelumab, Omalizumab, Monoclonal antibody, General Biochemistry, Genetics and Molecular Biology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Psoriasis, dupilumab, medicine, 030212 general & internal medicine, business.industry, General Medicine, Atopic dermatitis, psoriasis, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.disease, Dermatology, Dupilumab, Relative risk, Monoclonal, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.drug
Abstract: Les anticorps monoclonaux thérapeutiques en dermatologie ont d’abord été utilisés pour la prise en charge du psoriasis, puis, plus récemment, de l’urticaire chronique spontanée et de la dermatite atopique. Trois exemples seront abordés dans cette revue: le dupilumab, l’omalizumab et le lanadélumab. Leur mode d’action spécifique résulte d’une meilleure compréhension des mécanismes inflammatoires de ces maladies chroniques qui partageaient autrefois des traitements topiques ou systémiques plus ou moins ciblés. Leur utilisation onéreuse doit cependant être raisonnée par la mise en perspective de l’épidémiologie, de l’évaluation précise de la sévérité, de l’optimisation des traitements de première ligne, et de la balance bénéfices/risques.
Published: 2019
Full Text: View/download PDF

22. Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab

Author: Angèle Soria, Delphine Staumont-Sallé, Marie Jachiet, Julien Seneschal, Sébastien Barbarot, Aurélie Du-Thanh, CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Service de dermatologie Hôpital Saint-André Bordeaux, CHU Bordeaux [Bordeaux], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de dermatologie [Nantes], and Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Subjects: medicine.medical_specialty, Exacerbation, business.industry, Nasopharyngitis, Interleukin, Dermatology, Atopic dermatitis, Eosinophil, medicine.disease, Placebo, Dupilumab, 3. Good health, body regions, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Post-hoc analysis, Research Letter, Medicine, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; The efficacy and safety of dupilumab, a humanized monoclonal antibody targeting the α subunit of the interleukin (IL)-4 and IL-13 receptors, has been assessed in adults with moderate-to-severe atopic dermatitis (AD).1,2 Injection site reactions, nasopharyngitis, conjunctivitis, and transient increases in eosinophil counts from baseline were higher in the dupilumab groups than in the placebo groups in pivotal studies.1,2 A recent study by Zhu et al3 reported new regional dermatoses in 17 patients with AD treated with dupilumab, with facial area involvement in 14 cases, whereas Blauvelt et al4 reported an equal improvement of AD with dupilumab on different anatomic regions in a post hoc analysis of data extracted from 4 phase 3 clinical trials.
Published: 2019
Full Text: View/download PDF

23. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Author: A. Schoeffler, Ziad Reguiai, Audrey Lasek, Anne-Sophie Dillies, Jonathan Giovannelli, Nadia Raison-Peyron, Marie-Christine Ferrier le Bouedec, Aurélie Du Thanh, Sarah Faiz, Anne Dompmartin, Laurent Misery, Marie-Aleth Richard, J. Delaunay, Jean-Philippe Lacour, Sandrine Rappelle-Duruy, Jean-Philippe Arnault, Céline Podevin, Anne-Bénédicte Duval-Modeste, Jean-David Bouaziz, Angèle Soria, Amélie Walter-Lepage, Julien Sénéchal, Delphine Staumont-Sallé, François Aubin, Catherine Droitcourt, N. Bellon, Sébastien Barbarot, Stéphane Barete, Florence Tetart, Marie Jachiet, Emmanuel Mahé, Nathalie Beneton, Edouard Begon, Audrey Nosbaum, A. Valois, C. Morice, Service de Dermatologie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Polyclinique Courlancy (PC), Polyclinique de Courlancy, Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Saint Vincent de Paul de Lille, Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Université de Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de dermatologie, Hôpital Augustin Morvan-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Dermatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie et pathologies vasculaires [CH Argenteuil], Centre Hospitalier Victor Dupouy, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Centre Hospitalier René Dubos [Pontoise], CHU La Milétrie, Université de Picardie Jules Verne (UPJV), Service de Dermatologie, Hôpital Joseph Imbert, Centre Hospitalier d'Arles, CHU Pitié-Salpêtrière [AP-HP], Service de dermatologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Le Mans (CH Le Mans), Hôpital d'Instruction des Armées Sainte Anne, Service de Santé des Armées, Neurofibromatosis Clinic, Centre hospitalier universitaire de Nantes (CHU Nantes), Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CCSD, Accord Elsevier, Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Augustin Morvan, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Adult, Male, medicine.medical_specialty, Injections, Subcutaneous, [SDV]Life Sciences [q-bio], Kaplan-Meier Estimate, Dermatology, Antibodies, Monoclonal, Humanized, Risk Assessment, Severity of Illness Index, Eczema Area and Severity Index, Drug Administration Schedule, Dermatitis, Atopic, Cohort Studies, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Internal medicine, dupilumab, medicine, conjunctivitis, Humans, SCORAD, Adverse effect, Proportional Hazards Models, Retrospective Studies, Dose-Response Relationship, Drug, medicine.diagnostic_test, business.industry, Antibodies, Monoclonal, Atopic dermatitis, Dermatology Life Quality Index, medicine.disease, adultsatopic dermatitis, Dupilumab, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, Cohort, biotherapy, Female, France, Patient Safety, business, eosinophilia
Abstract: International audience; BackgroundDupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.ObjectiveWe sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.MethodsWe included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.ResultsWe included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10−9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10−9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10−6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs.LimitationsNo control group, missing data.ConclusionThis real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.
Published: 2019
Full Text: View/download PDF

24. Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients

Author: Laurence Bouillet, Isabelle Boccon-Gibod, Aurélie Du Thanh, Charles Faisant, Alban Deroux, C. Mansard, Centre Hospitalier Universitaire [Grenoble] (CHU), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
Subjects: Adult, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Immunology, Omalizumab, Immunoglobulin E, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Medical microbiology, Anti-Allergic Agents, medicine, Humans, Immunology and Allergy, Angioedema, Adverse effect, Chronic urticaria, Aged, 80 and over, non-histaminergic angioedema, biology, business.industry, Histaminergic, Middle Aged, Dermatology, 3. Good health, Treatment Outcome, 030228 respiratory system, Anesthesia, Disease Progression, Histamine H1 Antagonists, biology.protein, omalizumab, Female, Symptom Assessment, medicine.symptom, Idiopathic angioedema, business, Biomarkers, medicine.drug, Rare disease
Abstract: International audience; Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease characterized by AE resistant to antihistamines and a chronic course. We report five new cases of InH-AAE (two women and three men) with a rapid and dramatic response to the anti-immunoglobulin-E antibody omalizumab. In our literature review, we found 13 other relevant cases with a good response to this treatment. Overall, in 6 out of 18 patients, the doses of omalizumab required to prevent recurrences of attacks were higher than the licensed dose for chronic urticaria. No significant adverse effects have been reported.
Published: 2016
Full Text: View/download PDF

25. Severe allergic contact dermatitis caused by octylisothiazolinone in a leather sofa: two new cases

Author: C. Pecquet, Nadia Raison-Peyron, Sandra Apers, Aurélie Du-Thanh, Tania Naessens, Emmanuelle Amsler, and Olivier Aerts
Subjects: medicine.medical_specialty, business.industry, Dermatology, medicine.disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Methylisothiazolinone, Immunology and Allergy, Medicine, 030212 general & internal medicine, business, Allergic contact dermatitis
Published: 2017
Full Text: View/download PDF

26. Management of urticaria by French specialists compared to international guideline recommendations

Author: F. Hacard, Ismael Maatouk, Marie-Sylvie Doutre, C. Goujon Henry, Claire Bernier, C. Bara, C. Martinache, Frédéric Bérard, Boutros Soutou, Germaine Gabison, Audrey Nosbaum, J. Delaunay, I. Boccon Gibod, M.T. Guinepain, P. Mathelier Fusade, P. Pralong, Ryad Boussaid, Aurélie Du Thanh, F. Cambazard, S. Lefevre, Antoine Badaoui, Z. Bachtarzi, Laurence Bouillet, Angèle Soria, Florence Castelain, M. Vigan, M.E. Sarre, Jean-François Nicolas, C. Vermeulen, D. Staumont, C. Hoarau, Manuelle Viguier, C. Barzegar, C. Pouplard, Marie-Noëlle Crépy, F. Augey, Florence Tetart, Emmanuelle Amsler, N. Marmion, CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Subjects: medicine.medical_specialty, Urticaria, MEDLINE, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Specialization (functional), medicine, MESH: Urticaria, Humans, Immunology and Allergy, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, ComputingMilieux_MISCELLANEOUS, MESH: Humans, business.industry, MESH: Chronic Disease, MESH: Quality of Life, Guideline, Chronic disease, 030228 respiratory system, Family medicine, Chronic Disease, Quality of Life, MESH: Specialization, business, Specialization
Abstract: International audience
Published: 2020
Full Text: View/download PDF

27. Risque de cancers cutanés sous hydrochlorothiazide : revue systématique

Author: Bernard Guillot, O. Becquart, J.-L. Bourrain, Aurélie Du-Thanh, C. Duflos, and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Subjects: Drug, medicine.medical_specialty, media_common.quotation_subject, [SDV]Life Sciences [q-bio], Population, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Hydrochlorothiazide, Epidemiology, Internal Medicine, medicine, Basal cell carcinoma, Cancers cutanés, education, media_common, education.field_of_study, business.industry, Melanoma, Gastroenterology, medicine.disease, Dermatology, 3. Good health, Épidémiologie, 030220 oncology & carcinogenesis, Relative risk, Skin cancer, business, medicine.drug
Abstract: International audience; Le risque de cancers cutanés induits par des médicaments photosensibilisants est connu. Le rôle de l’hydrochlorothiazide a été soulevé par plusieurs études épidémiologiques récentes. Une revue systématique des études cas-témoins ou de cohortes prospectives montre qu’il existe un surrisque de carcinomes épidermoïdes dans la majorité des études même si certains facteurs de confusion comme le tabac n’ont pas été pris en compte. Les données sont plus contradictoires pour les carcinomes basocellulaires et les mélanomes. Ces résultats ne remettent pas en cause le rapport bénéfice/risque de cette molécule, mais peuvent inciter à des mesures de prévention renforcées chez les malades pour lesquels une prescription d’hydrochlorothiazide est proposée : identifier les patients à risque de carcinomes cutanés, éviter si possible de prescrire cette molécule chez les patients immunodéprimés ou ayant un carcinome, effectuer un examen cutané régulier chez les malades recevant ce traitement au long cours.
Published: 2019
Full Text: View/download PDF

28. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

Author: Jochen Graff, Sylvia Dobo, Melanie Cornpropst, Emel Aygören-Pürsün, L. Fang, Desiree Clemons, Vesna Grivcheva-Panovska, T González-Quevedo, Aarnoud Huissoon, R. Lleonart, Massimo Triggiani, Marco Cicardi, Mauro Cancian, William P. Sheridan, Mark Gompels, Hilary Longhurst, Anette Bygum, Henriette Farkas, Jens Greve, Markus Magerl, William Rae, Aurélie Du-Thanh, Urs C. Steiner, Mar Guilarte, Tamar Kinaciyan, William B Smith, Marcus Maurer, Constance H. Katelaris, Maria L. Baeza, Phil Collis, Werner Aberer, Olivier Fain, Andrea Zanichelli, Goethe-University Frankfurt am Main, Service de Médecine Interne [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), and Publica
Subjects: 0301 basic medicine, Oral, Adult, Male, Administration, Oral, Pharmacology, Drug Administration Schedule, C1-inhibitor, Dose-Response Relationship, 03 medical and health sciences, Plasma kallikrein inhibitor, 0302 clinical medicine, Double-Blind Method, Plasma Kallikrein/antagonists & inhibitors, medicine, Humans, Enzyme Inhibitors, Plasma Kallikrein, Aged, biology, Dose-Response Relationship, Drug, business.industry, Angioedemas, Hereditary, Angioedemas, General Medicine, Kallikrein, Middle Aged, medicine.disease, 3. Good health, C1 esterase, 030104 developmental biology, Hereditary, 030228 respiratory system, Angioedemas, Hereditary/prevention & control, Hereditary angioedema, Enzyme Inhibitors/administration & dosage, Administration, biology.protein, Quality of Life, Female, Drug, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; BACKGROUND: Hereditary angioedema is a life-threatening illness caused by mutations in the gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of the kallikrein-bradykinin cascade. BCX7353 is a potent oral small-molecule inhibitor of plasma kallikrein with a pharmacokinetic and pharmacodynamic profile that may help prevent angioedema attacks.METHODS: In this international, three-part, dose-ranging, placebo-controlled trial, we evaluated four doses of BCX7353 (62.5 mg, 125 mg, 250 mg, and 350 mg once daily) for the prevention of angioedema attacks over a 28-day period. Patients with type I or II hereditary angioedema with a history of at least two angioedema attacks per month were randomly assigned to BCX7353 or placebo. The primary efficacy end point was the number of confirmed angioedema attacks. Key secondary end points included angioedema attacks according to anatomical location and quality of life.RESULTS: A total of 77 patients underwent randomization, 75 received BCX7353 or placebo, and 72 completed the trial. The rate of confirmed angioedema attacks was significantly lower among patients who received BCX7353 at daily doses of 125 mg or more than among those who received placebo, with a 73.8% difference at 125 mg (P
Published: 2018
Full Text: View/download PDF

29. Place des traitements innovants du mélanome métastatique chez le sujet âgé

Author: Olivier Dereure, Aurélie Du-Thanh, Ernestine Ferreira, Bernard Guillot, and C. Lesage
Subjects: Drug, Oncology, medicine.medical_specialty, education.field_of_study, business.industry, medicine.medical_treatment, Mortality rate, media_common.quotation_subject, Melanoma, Population, Ipilimumab, Dermatology, Immunotherapy, medicine.disease, 3. Good health, Concomitant, Internal medicine, medicine, Vemurafenib, business, education, medicine.drug, media_common
Abstract: The mortality rate for malignant melanoma is higher in elderly patients aged 75 years or more, with over 25% of melanomas being diagnosed in this population. This poorer prognosis might perhaps be improved by emerging targeted therapies and immunotherapy, although these agents must be prescribed with care in this rather fragile population. The purpose of our review of the literature concerning phase-2 and -3 published trials of these innovative molecules was to examine their optimal use in elderly patients presenting metastatic malignant melanoma. Most of the trials examined included elderly patients and some were analyzed by age sub-groups. In conclusion, elderly patients with ECOG 0/1 status can be given ipilimumab or vemurafenib as first-line therapy depending on tumoral BRaf mutation status. The benefit of combined targeted therapies does not seem to apply consistently in elderly patients and their use must be discussed. Further specific data must be collected in elderly patients concerning anti-PD1 molecules. For more fragile patients, risk scales or scores should enable more accurate use of innovative therapies in metastatic melanoma. Moreover, physicians must be aware of the common drug interactions with targeted therapies, since elderly patients are often taking several concomitant drugs.
Published: 2015
Full Text: View/download PDF

30. Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients

Author: Djaouida Bengoufa, Jean-Luc Schmutz, Thierry Vincent, François Chasset, Jean-David Bouaziz, Anne Cosnes, Aurélie Du-Thanh, Nicolas Molinari, Nadège Cordel, T. Hubiche, Bernard Guillot, Y. Le Corre, Céline Girard, M. Best, Marie Jachiet, Valérie Pallure, F. Manna, M. Dandurand, Olivier Dereure, Didier Bessis, Camille Francès, Dan Lipsker, C. Bulai Livideanu, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Service de dermatologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Institut Montpelliérain Alexander Grothendieck ( IMAG ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Saint Jean de Perpignan, Service de dermatologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Université de Strasbourg ( UNISTRA ), CHU Strasbourg, Centre Hospitalier Intercommunal Fréjus - St Raphaël ( CHI Fréjus - St Raphaël ), Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Centre Hospitalier Universitaire d'Angers ( CHU Angers ), PRES Université Nantes Angers Le Mans ( UNAM ), CHU Pointe-à-Pitre/Abymes [Guadeloupe], Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ) -Centre Hospitalier Universitaire de Montpellier ( CHU Montpellier ), CHU Toulouse [Toulouse], Service de Dermatologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 ( UPD7 ) -CHU Saint Louis [APHP], Université de Montpellier ( UM ), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Montpelliérain Alexander Grothendieck (IMAG), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Strasbourg (UNISTRA), Centre Hospitalier Intercommunal Fréjus - St Raphaël (CHI Fréjus - St Raphaël), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Université de Montpellier (UM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], and Université Paris Diderot - Paris 7 (UPD7)-CHU Saint Louis [APHP]
Subjects: Adult, Male, medicine.medical_specialty, Interferon-Induced Helicase, IFIH1, Poikiloderma, Dermatology, Hand Dermatoses, Antibodies, Dermatomyositis, Amino Acyl-tRNA Synthetases, 030207 dermatology & venereal diseases, 03 medical and health sciences, Necrosis, Young Adult, 0302 clinical medicine, Calcinosis, Neoplasms, medicine, Humans, Prospective Studies, Prospective cohort study, Aged, Skin, 030203 arthritis & rheumatology, Adenosine Triphosphatases, Aged, 80 and over, business.industry, Interstitial lung disease, Autoantibody, Cancer, Odds ratio, Middle Aged, medicine.disease, 3. Good health, DNA-Binding Proteins, Infectious Diseases, Phenotype, Female, Joint Diseases, business, Lung Diseases, Interstitial, [ SDV.MHEP.DERM ] Life Sciences [q-bio]/Human health and pathology/Dermatology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Transcription Factors
Abstract: BACKGROUND: Identification of myositis-specific autoantibodies (MSAs) for dermatomyositis (DM) could allow the characterization of an antibody-associated clinical phenotype. OBJECTIVE: We sought to define the clinical phenotype of DM and the risk of cancer, interstitial lung disease (ILD) and calcinosis based on MSA. METHODS: A 3.5-year multicentre prospective study of adult DM patients was conducted to determine the clinical phenotype associated with MSAs and the presence of cancer, ILD and calcinosis. RESULTS: MSAs were detected in 47.1% of 117 included patients. Patients with antimelanoma differentiation-associated protein-5 antibodies (13.7%) had significantly more palmar violaceous macules/papules [odds ratio (OR) 9.9], mechanic's hands (OR 8), cutaneous necrosis (OR 3.2), articular involvement (OR 15.2) and a higher risk of ILD (OR 25.3). Patients with antitranscriptional intermediary factor-1 antibodies (11.1%), antinuclear matrix protein-2 antibodies (6.8%) and antiaminoacyl-transfer RNA synthetase (5.1%) had, respectively, significantly more poikiloderma (OR 5.9), calcinosis (OR 9.8) and articular involvement (OR 15.2). Cutaneous necrosis was the only clinical manifestation significantly associated with cancer (OR 3.1). CONCLUSION: Recognition of the adult DM phenotype associated with MSAs would allow more accurate appraisal of the risk of cancer, ILD and calcinosis.
Published: 2017
Full Text: View/download PDF

31. Abstracts from the 10th C1-inhibitor deficiency workshop

Author: Mikhail Belevtsev, Jens Greve, Pierre-Yves Jeandel, Ana Maria Gallardo-Olivos, William R. Lumry, Yael Laitman, Marc A. Riedl, Jean-Nicolas Boursiquot, Dasha Roa, Péter Závodszky, Kraig Jacobson, Susanne Trainotti, Maria Staevska, Márcia Gonçalves Ribeiro, Zeynep Gutowski, François Marceau, Alejandra Menendez, Eric Wagner, Y. Ollivier, Alvin H. Schmaier, Rolando Campilay-Sarmiento, Amin S. Kanani, Valeria Bafunno, Christine Symons, Svetlana Aleshkevich, Stephanie K. A. Almeida, Kusumam Joseph, Teresa Caballero, Hava Golander, Nancy J. Brown, Xavier Charest-Morin, Peter Banovcin, Arnaud Bonnefoy, Sajedeh Mohammadian, Mustafa Shennak, William P. Sheridan, Ira Kalfus, Claudio M. Costa-Neto, Rafael Filippelli-Silva, Anete Sevciovic Grumach, Solange Oliveira Rodrigues Valle, Oscar M. E. Calderón-Llosa, Panagiota Gianni, Emel Aygören-Pürsün, Rosemeire Navickas Constantino-Silva, Zsuzsanna Németh, Irmgard Andresen, Konrad Bork, Mauro Cancian, Claire de Moreuil, Janne Björkander, Melissa I. Espinosa, Tamás Szilágyi, Maria Rosario-Grauert, Jane da Silva, Michael Bader, Ying Zhang, Jana Hanzlíková, Sylvia Dobo, Carl-Fredrik Wahlgren, Jacquie Badiou, Diego A. Duarte, Marta Del Medico, Stefania Loffredo, Avner Reshef, Maria Palasopoulou, Ludmila Vavrova, Marie Dubrel, Raheleh Shokouhi Shoormasti, Bruce L. Zuraw, Susan Nabilou Deshiry, Shiva Saghafi, Ekaterina Polyakova, Matthieu Vincent, Douglas J. Watson, Mohammad Reza Fazlollahi, Anne Rowe, Shawn Qian, Blanca Sáenz de San Pedro, Christelle Pommie, Sofía Garrido, Sandra Mitie Ueda Palma, András Szilágyi, Luis Fernando Landivar-Salinas, Audrey Lehmann, Maria L. Baeza, Kiana Bidad, Hugo Chapdeleine, Stéphane Gayet, Davide Firinu, Nancy Payette, Christine Pajot, Nyla Melo, Pavel Kuklínek, Pablo Raby, Nóra Veszeli, Ingo Pragst, Desiree Clemons, Anne Pagnier, Attila Mócsai, Carmen Escuriola Ettingshausen, Henrike Feuersenger, Noémi Andrási, Paul K. Keith, Phil Collis, Ernie Avilla, Olivier Fain, Iris Leibovich-Nassi, Dario O. Josviack, Jiří Litzman, Con Panousis, Denise Ponard, Sébastien Trouiller, Ráhel Dani, Francesco Casella, Ana Rodríguez, Isabelle Boccon-Gibod, Nada Afifi Afifi, Olga M. Barrera, Gina Lacuesta, Gian Marco Podda, Anne Lise Ferrara, Samuel Luyasu, Ludovic Martin, Patrik Nordenfelt, Linda Howlett, William H. Yang, Sandra A. Nieto, Anders Lindfors, Zahra Pourpak, Stéphanie Amarger, Adriana Hernanz, Jochen Hardt, Julian Rodriguez-Galindo, Claire Blanchard-Delaunay, Antonio Castelli, Marta Sánchez-Jareño, Renata Martins, Bertrand Favier, Yi Wang, Rosario Cabañas, Anthony Roberts, Renan Paulo Martin, Alexandre Belot, Vincenzo Montinaro, Eitan Friedman, João Bosco Pesquero, Maria Kompoti, Bruna Franca Azevedo, Mikolajczyk Tomasz, Georges-É. Rivard, Katalin Várnai, Gábor Oroszlán, Arije Ghannam, David Launay, Fotis Psarros, Manuel Ratti, Maria Luiza Oliva Alonso, Bernard Floccard, Mariana Lluncor, Karen Binkley, Gianni Marone, Anne Gompel, Dominik Gulyás, John Dempster, Liudmyla Zabrodska, Emanuele Catena, Anna Bogdali, Irina Guryanova, Andrej Salivonchik, Camila Lopes Veronez, L. Fang, Eleonora Tobaldini, Lilian Varga, Chiara Suffritti, Daniel Vaszquez, Peter Waite, Maria Zamanakou, Ana Alvez, Laurence Bouillet, Péter Gál, Susan Waserman, Krystyna Obtułowicz, Marcin Stobiecki, Alain Sobel, Karin Wulff, A. Z. Sin, Margarita Olivares, Dipti Pawaskar, Mats Nilsson, Endre Schwaner, Brigitte Coppere, Anna Valerieva, Remi Gagnon, Marlon J. O. Carabantes, Stefano Pizzimenti, H. Onay, Paula J. Busse, Delphine Charignon, William Rae, Marco Cicardi, Kinga Viktória Kőhalmi, Inmaculada Martinez-Saguer, Daniel J. Sexton, Matthaios Speletas, Aarnoud Huissoon, René Bailleau, Fabien Pelletier, Elena Petkova, Joanna Araujo Simoes, Guillaume Armengol, Amanda Mathis, Rosangela P. Tortora, Raz Somech, Andreas Gille, Anastasios E. Germenis, Martin Hrubisko, Marylin Desjardins, Dorottya Csuka, María Pedrosa, Jose Fabiani, Stephen Betschel, Timothy J. Craig, Vasil Dimitrov, Andrew McDonald, Alberto López Lera, Márta L. Debreczeni, Eli Mansour, Teofila Książek, Teófilo Lobera, Rozita Borici-Mazi, O. Gulbahar, Aleena Banerji, Jochen Graff, Marta Sobotkova, Annette Feussner, Andrea Zanichelli, Ewa Czarnobilska, Anna Koncz, Milos Jesenak, Edison Zapata-Venegas, Aurore Billebeau, Gedeon Loules, Melanie Nordmann-Kleiner, Werner Aberer, Richard Linde, Guenther Witzke, Kristina Lis, Markus Magerl, Jana Strenková, Emmanouil Manoussakis, József Dobó, Viktar Lebedz, Masumi Grau, Raquel Martins, Melanie Cornpropst, Jovanna Baptista, Marcus Maurer, Dumitru Moldovan, György Temesszentandrási, Isabelle Boccon-Gibbod, Thomas Machnig, C Marcos, Erika Kajdácsi, Tim Green, John Anderson, Karin Andritschke, D. Soteres, Riccardo Colombo, Mario Martinez Alfonso, Anna Radice, Huamin Henry Li, Tsvetelina Velikova, Ruggero Di Maulo, Mariela Borisova Vasileva, Angelica Petraroli, Francesca Perego, Francisco A. Contreras, Roman Hakl, Urs C. Steiner, Anurag Relan, N. Prior, Irena Krčmová, Jennifer Schranz, Martina Vachová, Baby G. Tholanikunnel, R. Lleonart, Maria Bova, Allen P. Kaplan, N. M. Gokmen, Nicola Montano, Margarita López-Trascasa, Tiziana Maria Angela De Pasquale, Alicia Prieto, Kristian Buur Kreiberg, Mohammad Hassan Bemanian, Alessandra Zoli, Michael A. Tortorici, Erika J. Sifuentes, László Cervenak, Borislava Krusheva, Maria E. Hernandez-Landeros, Wojciech Dyga, Oleksandra Lepeshkina, Elma Nievas, L. Bellizzi, Christian Drouet, C. Mansard, Michel Bouvier, Aurélie Du Thanh, Donatella Lamacchia, Janina Hahn, Radana Zachova, Iraj Mohammadzadeh, T González-Quevedo, Z. P. Koc, Jacques Hébert, Hilary Longhurst, Maddalena Alessandra Wu, Ariane Zélinsky-Gurung, Jim Christensen, Maurizio Margaglione, Maryam Ayazi, Vesna Grivcheva Panovska, Faidra Parsopoulou, Jonathan A. Bernstein, Anette Bygum, Seyed Alireza Mahdaviani, Henriette Farkas, Aleksander Obtułowicz, Natalia Fili, Gisèle Kanny, Gerasimina Tsinti, Alfeu Tavares França, George N. Konstantinou, Benoit Laramée, Katarina Hrubiskova, Lisa Fu, J. Laurent, and Arthur Van Leerberghe
Subjects: lcsh:Immunologic diseases. Allergy, 0301 basic medicine, 03 medical and health sciences, 030102 biochemistry & molecular biology, C1 inhibitor deficiency, business.industry, Immunology, Medicine, General Medicine, lcsh:RC581-607, business, Meeting Abstracts
Published: 2017
Full Text: View/download PDF

32. Macrophage activation syndrome: A new complication of checkpoint inhibitors

Author: Jean-Jacques Grob, N. Malissen, Julie Lacotte, Aurélie Du-Thanh, Caroline Gaudy-Marqueste, Bernard Guillot, Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
Subjects: 0301 basic medicine, Cancer Research, Cell cycle checkpoint, Immune checkpoint inhibitors, Ipilimumab, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, 0302 clinical medicine, Medicine, ComputingMilieux_MISCELLANEOUS, biology, business.industry, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Macrophage activation syndrome, Cancer research, biology.protein, Nivolumab, Antibody, Complication, business, B7-H1 Antigen, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug
Abstract: International audience
Published: 2017
Full Text: View/download PDF

33. Normal PAI-2 level in French FXII-HAE patients

Author: Raphaël Marlu, Laurence Bouillet, Isabelle Boccon-Gibod, Alban Deroux, Aurélie Du-Thanh, David Launay, Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Thérapeutique Recombinante Expérimentale [?-2015] (TIMC-TheREx [?-2015]), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 [2011-2015] (TIMC [2011-2015]), Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)-IMAG-Institut polytechnique de Grenoble - Grenoble Institute of Technology [2007-2019] (Grenoble INP [2007-2019])-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)-IMAG-Institut polytechnique de Grenoble - Grenoble Institute of Technology [2007-2019] (Grenoble INP [2007-2019])-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS), Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CREAK Grenoble, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de Médecine Interne, CHU Grenoble, and Service de médecine interne [Lille]
Subjects: 030201 allergy, medicine.medical_specialty, business.industry, [SDV]Life Sciences [q-bio], Immunology, Angioedemas, Hereditary, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, 030228 respiratory system, Internal medicine, Plasminogen activator inhibitor-2, Plasminogen Activator Inhibitor 2, medicine, Humans, Immunology and Allergy, [SDV.IMM]Life Sciences [q-bio]/Immunology, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, business, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience
Published: 2017
Full Text: View/download PDF

34. Unusual Facial 'Acne': A Quiz

Author: Olivier Dereure, Luc Durand, Aurélie Du-Thanh, Valérie Costes, Eric Frouin, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Service de Biopathologie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
Subjects: Adult, medicine.medical_specialty, Skin Neoplasms, Biopsy, Physical examination, Dermatology, Asymptomatic, Lymphocytic Infiltrate, Diagnosis, Differential, Predictive Value of Tests, Acne Vulgaris, medicine, Biomarkers, Tumor, Humans, ComputingMilieux_MISCELLANEOUS, Skin, medicine.diagnostic_test, business.industry, Papule, General Medicine, Lymphoma, B-Cell, Marginal Zone, Immunohistochemistry, Chin, medicine.anatomical_structure, Abdomen, Female, medicine.symptom, Differential diagnosis, business, [ SDV.MHEP.DERM ] Life Sciences [q-bio]/Human health and pathology/Dermatology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; A 31-year-old woman was investigated for multiple, slightly erythematous or flesh-coloured, firm, asymptomatic papu-les, a few mm in diameter, located exclusively on the chin and the lower part of both cheeks (Fig. 1a). These elements had gradually emerged over the 2 previous years and were initially considered and treated unsuccessfully as retentional acne. Physical examination was otherwise unremarkable and the general status of the patient was excellent. Histo-logical examination of a papule displayed a multi-nodular lymphocytic infiltrate of moderate density involving the upper and medium dermis that was well-limited laterally (Fig. 1b). Standard laboratory investigations and routine serologies, including serological diagnosis of Borrelia, were normal or negative. Computed tomography (CT) scan of the chest, abdomen and pelvis was unremarkable. What is your diagnosis? See next page for answer. Fig. 1. Clinical and histological features. (a) Multiple, small-sized papules of the lower part of the face with chronic evolution. (b) multi-nodular dermal infiltrate of moderate density involving the upper and medium dermis with reactive germinal centre-like structures (Haematoxylin-eosin ×5).
Published: 2017
Full Text: View/download PDF

35. High Expression of Fas/CD95 on CD4+ Circulating T Cells: An Exclusion Criterion in the Diagnosis of Mycosis Fungoides?

Author: Aurélie Du-Thanh, Olivier Dereure, Céline Girard, Pierre Portales, Anne Serre-Cousiné, Bernard Guillot, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
Subjects: 0301 basic medicine, CD4-Positive T-Lymphocytes, Male, Pathology, Skin Neoplasms, Fas/Fasligandsystem, CD95expression, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, lcsh:Dermatology, Medicine, Prospective Studies, Prospective cohort study, Aged, 80 and over, medicine.diagnostic_test, General Medicine, mycosisfungoides, Middle Aged, Fas receptor, Flow Cytometry, Prognosis, Peripheral, Up-Regulation, Phenotype, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, Predictive value of tests, Area Under Curve, Female, Adult, medicine.medical_specialty, Dermatology, Flow cytometry, 03 medical and health sciences, Mycosis Fungoides, Predictive Value of Tests, Psoriasis, Biomarkers, Tumor, Humans, fas Receptor, Aged, Mycosis fungoides, peripheralbloodCD4+CD95+rate, Fas/Fas ligand system, business.industry, Case-control study, peri pheral blood CD4 + CD95 + rate, Reproducibility of Results, lcsh:RL1-803, medicine.disease, 030104 developmental biology, ROC Curve, Case-Control Studies, business, CD95 expression, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; The aim of this 10-year monocentric prospective study was to determine a cut-off value of Fas/CD95 expression by peripheral blood CD4+ T lymphocytes in discriminating patients with mycosis fungoides from controls with cutaneous benign lymphocytic conditions. CD95 expression in peripheral blood CD4+ T lymphocytes was measured using flow cytometry in 330 patients referred for diagnosis: 104 with mycosis fungoides and 226 with eczema, psoriasis, drug reaction, etc. The sensitivity and specificity of different thresholds of CD95 expression were calculated regarding the final diagnosis of patients with mycosis fungoides or controls. CD95 expression higher than 30% reached a specificity of 91% in ruling out a diagnosis of mycosis fungoides, although overall CD95 expression was not significantly different from that of controls (p = 0.309) and sensitivity was very low (5%). Thus, peripheral CD95 expression higher than 30% could be used among the exclusion criteria in a multicomponent score for mycosis fungoides diagnosis.
Published: 2017
Full Text: View/download PDF

36. Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema

Author: Pauline Pralong, Aurélie Du-Thanh, Anne Gompel, Alban Deroux, Olivier Fain, Laurence Bouillet, Y. Ollivier, Isabelle Boccon-Gibod, Charles Faisant, Anne Pagnier, Kamel Djenouhat, David Launay, Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service de Médecine Interne [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Grenoble, Service de médecine interne [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Gynécologie et Obstétrique [Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Lille Inflammation Research International Center - U 995 (LIRIC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Service de médecine interne [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: Adult, Male, Adolescent, Pregnancy Complications, Cardiovascular, Immunology, Asymptomatic, Contraceptives, Oral, Hormonal, C1-inhibitor, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pregnancy, Icatibant, Humans, Immunology and Allergy, Medicine, Family, Child, C1 inhibitor, Angioedema, biology, business.industry, factor XII, Angioedemas, Hereditary, Original Articles, medicine.disease, hereditary angioedema, 3. Good health, Tranexamic Acid, 030228 respiratory system, chemistry, Mutation, Hereditary angioedema, biology.protein, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, France, medicine.symptom, bradykinin, business, Complement C1 Inhibitor Protein, Tranexamic acid, Rare disease, medicine.drug
Abstract: Summary Hereditary angioedema (HAE) is a rare disease associated with either a quantitative or qualitative deficiency in C1-inhibitor (C1-INH) or normal C1-INH. HAE with normal C1-INH is associated in 20% of cases with mutations in the gene for factor XII (FXII) or FXII-HAE. A recent review described 41 families, including 14 German and 15 Spanish families. We have constructed a register of French patients and their characteristics. A national survey was launched through the French National Center of Reference for Angioedema (CREAK) to study the clinical, biological and therapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. In most cases they were young women (mean age at diagnosis: 31 years, mean age at first symptom: 21 years, female/male ratio: 76%). Twenty-one per cent of the patients experienced angioedema attacks only during pregnancy or when on oestrogen contraception. Sixty-three per cent had attacks at all times, but they were more severe during these same periods. Male carriers of the mutation were more frequently asymptomatic than females (P = 0·003). C1-INH concentrate and icatibant were both effective for treating attacks. The prophylactic use of tranexamic acid led to a 64% decrease in the number of attacks. This is one of the largest series reported of HAE patients with FXII mutation. The therapeutic management appeared to be identical to that of HAE with C1-INH deficiency.
Published: 2016
Full Text: View/download PDF

37. Symmetrical Intertriginous and Flexural Exanthema due to Bortezomib (a Proteasome Inhibitor) Given for Myeloma

Author: Olivier Dereure, Aline Montet, Laure Vincent, Aurélie Du-Thanh, Jean-Luc Bourrain, Nausicaa Malissen, Anca Mirela Chiriac, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
Subjects: Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, Dermatology, Intertriginous, Pharmacology, Bortezomib, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Flexural strength, medicine, Humans, ComputingMilieux_MISCELLANEOUS, business.industry, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, General Medicine, Exanthema, Middle Aged, 3. Good health, 030228 respiratory system, Proteasome inhibitor, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Drug Eruptions, business, Multiple Myeloma, Proteasome Inhibitors, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.drug
Abstract: International audience
Published: 2016
Full Text: View/download PDF

38. Actinic keratosis: when is a skin biopsy necessary?

Author: Aurélie Du Thanh and Bernard Guillot
Subjects: medicine.medical_specialty, Skin Neoplasms, Keratosis, Biopsy, Dermoscopy, Physical examination, Dermatology, Risk Assessment, Diagnosis, Differential, Lesion, Risk Factors, medicine, Carcinoma, Humans, Invasive carcinoma, medicine.diagnostic_test, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Actinic keratosis, Phototherapy, medicine.disease, Keratosis, Actinic, Treatment Outcome, Cryotherapy, Skin biopsy, Carcinoma, Squamous Cell, Disease Progression, Drug Therapy, Combination, medicine.symptom, business, Immunosuppressive Agents
Abstract: The diagnosis of actinic keratosis is generally established by clinical examination. However, actinic keratosis can progress into an invasive squamous cell carcinoma, therefore biopsy and histological examination may be needed. The risk of progression into an invasive carcinoma is not well established; it varies in the literature between 0.025% and 20% for a given lesion. Some clinical aspects suggest transformation into an invasive carcinoma; they include inflammation, induration, size > 1 cm, rapid enlargement of the lesion, bleeding or ulceration, and should prompt the clinician to perform a skin biopsy. In case of resistance after a well-driven treatment, a biopsy may be necessary. Finally, in cases of atypical clinical aspect, a biopsy may be useful in order to obtain a correct diagnosis.
Published: 2012
Full Text: View/download PDF

39. No Viral Transcripts Associated with Folliculotropic Mycosis Fungoides Using a High Throughput Sequencing Approach

Author: Marc Eloit, Liza Al-Shikhley, Bernard Guillot, Céline Girard, Justine Cheval, Olivier Dereure, Marine Dumarest, Aurélie Du-Thanh, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Laboratoire d'Excellence [ANR-10-LABX-62-IBEID], and Du-Thanh, Aurelie
Subjects: Adult, Male, Biopsy, [SDV]Life Sciences [q-bio], Dermatology, viruses, cell, lymphoma, samples, Mycosis Fungoides, Medicine, Humans, Viral, Throughput (business), ComputingMilieux_MISCELLANEOUS, Skin, Aged, Mycosis fungoides, Hardware_MEMORYSTRUCTURES, medicine.diagnostic_test, business.industry, High-Throughput Nucleotide Sequencing, General Medicine, Middle Aged, medicine.disease, Folliculotropic Mycosis Fungoides, Virology, 3. Good health, RL1-803, RNA, Viral, RNA, business
Abstract: is missing (Short communication)
Published: 2017
Full Text: View/download PDF

40. Atypical and severe airborne isothiazolinone contact dermatitis mimicking Kaposi-Juliusberg syndrome

Author: Olivier Dereure, Muriel Lalande, Nadia Raison-Peyron, and Aurélie Du-Thanh
Subjects: medicine.medical_specialty, business.industry, Dermatology, 010501 environmental sciences, medicine.disease, 01 natural sciences, Isothiazolinone, 030207 dermatology & venereal diseases, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Immunology and Allergy, Medicine, business, Contact dermatitis, 0105 earth and related environmental sciences
Published: 2017
Full Text: View/download PDF

41. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study

Author: Olivier Dereure, Eric Estève, Pascal Joly, C. Pauwels, Bernard Guillot, Aurélie Du-Thanh, Saskia Ingen-Housz-Oro, Hervé Maillard, S. Merlet, P. Bernard, and M.-A. Richard
Subjects: medicine.medical_specialty, business.industry, Retrospective cohort study, Dermatology, medicine.disease, Discontinuation, law.invention, Surgery, Regimen, Pharmacotherapy, Randomized controlled trial, law, Internal medicine, Medicine, Methotrexate, Bullous pemphigoid, Adverse effect, business, medicine.drug
Abstract: Summary Background The interest of long-term superpotent topical steroids (STS) in bullous pemphigoid (BP) has been supported by randomized controlled trials. However, inadequate compliance, poor cutaneous tolerance and nursing difficulties are potential drawbacks. Open-label studies on limited series of patients suggested that low-dose methotrexate (MTX) may be useful, permitting long-term maintenance of a clinical remission obtained by initial, short-term STS. Objectives Open, clinical records-based retrospective analysis of a multicentre series of patients receiving a combined regimen of initial, short-term STS and MTX followed by long-term MTX alone. The primary objective was evaluation of the clinical efficiency of this strategy based on initial clinical remission and subsequent clinical maintenance. The secondary objective was evaluation of the tolerance (type and rating of adverse events) of this combined regimen. Methods Seventy patients with BP (mean age 82·7 years) were included. Treatment consisted of an initial combination of STS and MTX for a mean duration of 12·3 weeks followed by long-term MTX alone for a mean duration of 8·48 months with a mean and median MTX dosage of 10 mg per week. Results One hundred per cent of the patients showed an initial, complete clinical remission after a mean time interval of 21·9 days. The overall rate of long-term disease control was 76%, whereas 24% of patients experienced at least one relapse during subsequent treatment with MTX alone. Drug-related adverse effects were mainly haematological and gastrointestinal and resulted in treatment discontinuation in 11 patients (16%). Six patients (9%) died during the follow-up period with one death (1%) most likely to be related to treatment. Conclusions Long-term low-dose MTX combined with short-term STS may result in protracted control of BP in carefully selected patients. These results should prompt randomized controlled trials comparing this treatment with the more usual regimen of long-term STS alone.
Published: 2011
Full Text: View/download PDF

42. Les angioedèmes à bradykinine

Author: Nadia Raison-Peyron, Bernard Guillot, and Aurélie Du-Thanh
Subjects: business.industry, Medicine, Dermatology, business
Published: 2011
Full Text: View/download PDF

43. Interest of (18)F-FDG PET-CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients

Author: Denis Mariano-Goulart, Bernard Guillot, Olivier Dereure, Aurélie Du-Thanh, and G. Maury
Subjects: medicine.medical_specialty, medicine.diagnostic_test, business.industry, Merkel cell carcinoma, Sentinel lymph node, Physical examination, Retrospective cohort study, Dermatology, medicine.disease, Infectious Diseases, Text mining, Biopsy, medicine, Fdg pet ct, Radiology, Tomography, business, Nuclear medicine
Abstract: Background The additional benefit of 18FDG-Positron Emission Tomography-Computed Tomography (FDG PET-CT) compared with conventional imaging is still a controversial issue in MCC. Objectives This study was designed to evaluate the ability of FDG PET-CT to detect secondary lesions clinically inconspicuous and not shown by conventional imaging. Methods Clinical records of 15 MCC patients were retrospectively reviewed to investigate the specific interest of FDG PET-CT compared with X-computed tomography (CT). The main endpoint was the ability of FDG PET-CT to detect secondary lesions and the possible resulting changes in disease staging and management compared with pre-FDG PET-CT data including clinical examination, sentinel lymph node biopsy (SLNB), and diagnostic CT. Results FDG PET-CT was relevant with a single false negative result and led to significant changes in disease staging and management in 46% of patients compared with clinical examination alone. However, additional secondary lesions not detected by CT were evidenced during follow-up in a single patient with an already known metastatic disease, data which did not result in any change in staging and treatment. Sensitivity, specificity, positive predictive value and negative predictive value were respectively 0.66, 1, 1 and 0.8 for SLNB, 0.89, 1, 1 and 0.93 for CT and 0.89, 1, 1 and 0.93 for FDG PET-CT. No additional neoplasm was detected by FDG PET-CT. Conclusion Although FDG PET-CT is of questionable value in MCC management when used in parallel with CT, it may be considered as a valuable option as a single whole-body survey procedure.
Published: 2011
Full Text: View/download PDF

44. Cold Contact Urticaria Following Vaccination: Four Cases

Author: Nathalie Bernard, Annick Barbaud, Nadia Raison-Peyron, Didier Bessis, Aurélie Du-Thanh, Christelle Philibert, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
Subjects: Adult, Male, medicine.medical_specialty, Heptavalent Pneumococcal Conjugate Vaccine, Urticaria, Meningococcal Vaccines, Dermatology, Cryoproteins, 030207 dermatology & venereal diseases, 03 medical and health sciences, Contact urticaria, 0302 clinical medicine, immune system diseases, Medicine, Humans, Vaccines, Combined, Physical urticaria, skin and connective tissue diseases, Diphtheria-Tetanus-Pertussis Vaccine, Haemophilus Vaccines, Hepatitis A Vaccines, business.industry, Vaccination, Yellow Fever Vaccine, Cold air, Infant, General Medicine, medicine.disease, 3. Good health, Cold Temperature, Poliovirus Vaccine, Inactivated, 030228 respiratory system, Influenza Vaccines, Child, Preschool, Anaphylactic shock, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; Cold contact urticaria (CCU) is a physical urticaria, also called inducible urticaria, which is triggered by exposure of the skin to cold air, surfaces or fluids. Clinical manifestations of CCU range from mild, localized whealing to life-threatening anaphylactic shock. CCU is mostly idiopathic (primary), but in rare cases it is secondary to infectious disease, with or without cryoproteins. We report here, for the first time, 4 cases of CCU that developed following vaccination, which suggests a link between these events.
Published: 2016
Full Text: View/download PDF

45. Diagnosing pelvic osteomyelitis beneath pressure ulcers in spinal cord injured patients: a prospective study

Author: A.-S. Brunel, B. Lamy, C. Cyteval, H. Perrochia, L. Téot, R. Masson, H. Bertet, A. Bourdon, D. Morquin, J. Reynes, V. Le Moing, Isabelle Alméras, Aurélie Du Thanh, Anthony Gélis, Claire Reynaud, Hélène Rouays, Chloé Trial, Sergio Fliueraru, Christian Herlin, Jean-Philippe Lavigne, Christophe Delfour, Marie-Pierre Baron, Pierre Viala, Thibaut Mura, Philippe Géraud, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hydrosciences Montpellier (HSM), Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université de Montpellier (UM), Département Maladies Infectieuses et Tropicales, Hôpital Universitaire, Montpellier, France, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Euromov (EuroMov), CHU Montpellier, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Département de l'Information Médicale, and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie
Subjects: 0301 basic medicine, Microbiology (medical), Adult, Male, medicine.medical_specialty, Histology, 030106 microbiology, Comorbidity, medicine.disease_cause, 030207 dermatology & venereal diseases, 03 medical and health sciences, pressure ulcers, 0302 clinical medicine, Anti-Infective Agents, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Risk Factors, Biopsy, medicine, Humans, Prospective Studies, Prospective cohort study, Pelvic Bones, Pelvis, Spinal Cord Injuries, Aged, Pressure Ulcer, biology, medicine.diagnostic_test, Streptococcus, business.industry, Osteomyelitis, microbiology, General Medicine, Middle Aged, biology.organism_classification, medicine.disease, Magnetic Resonance Imaging, Peptostreptococcus, 3. Good health, Surgery, medicine.anatomical_structure, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Staphylococcus aureus, Female, business, Biomarkers
Abstract: International audience; There is no consensus on a diagnostic strategy for osteomyelitis underlying pressure ulcers. We conducted a prospective study to assess the accuracy of multiple bone biopsies and imaging to diagnose pelvic osteomyelitis. Patients with clinically suspected osteomyelitis beneath pelvic pressure ulcers were enrolled. Bone magnetic resonance imaging (MRI) and surgical bone biopsies (three or more for microbiology and one for histology per ulcer) were performed. Bacterial osteomyelitis diagnosis relied upon the association of positive histology and microbiology (at least one positive culture for non-commensal microorganisms or three or more for commensal microorganisms of the skin). From 2011 to 2014, 34 patients with 44 pressure ulcers were included. Bacterial osteomyelitis was diagnosed for 28 (82.3%) patients and 35 (79.5%) ulcers according to the composite criterion. Discrepancy was observed between histology and microbiology for 5 (11.4%) ulcers. Most common isolates were Staphylococcus aureus (77.1%), Peptostreptococcus (48.6%) and Bacteroides (40%), cultured in three or more samples in 42.9% of ulcers for S. aureus and ≥20% for anaerobes. Only 2.8% of ulcers had three or more positive specimens with coagulase-negative staphylococci, group B Streptococcus, and nil with enterococci and Pseudomonas aeruginosa. Staphylococcus aureus, Proteus and group milleri Streptococcus were recovered from one sample in 22.8%, 11.4% and 11.4% of ulcers, respectively. Agreement was poor between biopsies and MRI (κ 0.2). Sensitivity of MRI was 94.3% and specificity was 22.2%. The diagnosis of pelvic osteomyelitis relies on multiple surgical bone biopsies with microbiological and histological analyses. At least three bone samples allows the detection of pathogens and exclusion of contaminants. MRI is not routinely useful for diagnosis.
Published: 2015
Full Text: View/download PDF

46. Clostridium difficile infection may loom behind ipilimumab-induced auto-immune colitis

Author: Olivier Dereure, Bernard Guillot, Céline Girard, Valérie Pallure, Aurélie Du-Thanh, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )
Subjects: medicine.medical_specialty, medicine.medical_treatment, Dacarbazine, Ipilimumab, Dermatology, 03 medical and health sciences, 0302 clinical medicine, Immune system, medicine, Stage (cooking), Colitis, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, Chemotherapy, 030306 microbiology, business.industry, Clostridium difficile, medicine.disease, 3. Good health, Surgery, Diarrhea, 030220 oncology & carcinogenesis, medicine.symptom, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug
Abstract: We report here the first case of a misleading association of Clostridium difficile infection (CDI) with ipilimumab-related immune diarrhea in a patient with unresectable stage III melanoma.After an unsuccessful first-line chemotherapy with dacarbazine (1000 mg/m2 every three weeks) for a subcutaneous and nodal relapse of a stage IIb melanoma of the right lower limb (Breslow index 3.75 mm, Clark level IV), treated by surgical excision 11 months previously and incomplete adjuvant treatment with alpha [...]
Published: 2015
Full Text: View/download PDF

47. Recently discovered human polyomaviruses in lesional and non-lesional skin of patients with primary cutaneous T-cell lymphomas

Author: Vincent Foulongne, Olivier Dereure, Aurélie Du-Thanh, and Bernard Guillot
Subjects: Polyomavirus Infections, Pathology, medicine.medical_specialty, Primary (chemistry), business.industry, T cell, Dermatology, Real-Time Polymerase Chain Reaction, Primary cutaneous T-cell lymphoma, Biochemistry, Lymphoma, T-Cell, Cutaneous, Tumor Virus Infections, Mycosis Fungoides, medicine.anatomical_structure, Merkel cell polyomavirus, Immunology, Humans, Sezary Syndrome, Medicine, Polyomavirus, business, Molecular Biology, Skin
Published: 2013
Full Text: View/download PDF

48. Lits dédiés aux soins palliatifs dans un service de dermatologie

Author: C. Fabre, J. Chevallier-Michaud, Olivier Dereure, Bernard Guillot, D. Enjarlan, Aurélie Du-Thanh, and Céline Girard
Subjects: business.industry, Medicine, Library science, Dermatology, business
Published: 2011
Full Text: View/download PDF

49. Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema

Author: Christian Drouet, Bernard Guillot, Nadia Raison-Peyron, and Aurélie Du-Thanh
Subjects: Danazol, medicine.medical_specialty, Aspirin, Angioedema, business.industry, Immunology, Bradykinin, Chest pain, Gastroenterology, chemistry.chemical_compound, chemistry, Edema, Anesthesia, Internal medicine, medicine, Immunology and Allergy, medicine.symptom, Headaches, business, Tranexamic acid, medicine.drug
Abstract: Angioedema (AO) without urticaria is uncommon but may be life threatening. When AO is not controlled by H1anti-histamines or corticoids or adrenalin, and there is no medication with non steroid antiinflammatory drugs or aspirin, bradykinin AO (BAO) should be considered. Most of the BAO are caused by a hereditary or acquired deficient C1inhibitor, diagnosed by weight and function measurements. This deficiency leads to an accumulation of bradykinin, a vasopeptide responsible for the occurrence of edema (1). Possible treatments are the C1inhibitor concentrate, danazol which up regulates the C1inhibitor gene transcription and tranexamic acid (TA) which prevents the plasmin-dependent formation of bradykinin (2). In some rare cases, BAO have no deficient C1inhibitor. The accumulation of bradykinin can then be caused by stimulation of the kininogenases or by deficient kininases (3). Thus, three causes should be considered as follows: angiotensin convertase enzyme (ACE) inhibitors because ACE is a kininase and AO occur up to 1%; a type III hereditary AO in which gain-of-function mutations of the coagulation factor XII can be involved; and idiopathic bradykinin AO that can be either familial or sporadic. In contrast with the well-known hereditary AO, this subset seems to be less severe. It was specifically studied in only two major series but with sporadic and familial cases, which can represent at least two different entities (4, 5). A series of seven French sporadic cases was described by Bouillet et al. (6). By analogy with hereditary AO, daily TA was given to these patients with a good response up to 100%. In our retrospective study, we were interested in sporadic idiopathic BAO. Thirty-five patients between 2003 and 2007 were studied (Fig. 1). There were 14 women and 21 men (sex ratio, 0.66). The mean age at onset was 42 years (range, 3 months to 78 years). The mean age at diagnosis was 45.8 years; the mean diagnostic delay was 3.8 years (range, 0–15 years). The mean duration of the episode was 36.34 h (range, 1 h to 4 days). The rhythm varied from daily episodes to
Published: 2009
Full Text: View/download PDF

50. Absence of HTLV-Related Sequences in Skin Lesions and Peripheral Blood of Cutaneous T-Cell Lymphomas

Author: Marc Sitbon, Olivier Dereure, Aurélie Du-Thanh, Bernard Guillot, Valérie Courgnaud, Institut de Génétique Moléculaire de Montpellier (IGMM), and Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)
Subjects: Human T-lymphotropic virus 1, 0303 health sciences, Pathology, medicine.medical_specialty, Skin Neoplasms, business.industry, T cell, Cell Biology, Dermatology, Biochemistry, Peripheral blood, Lymphoma, T-Cell, Cutaneous, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, DNA, Viral, Humans, Medicine, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, business, Skin lesion, Molecular Biology, Skin, 030304 developmental biology
Published: 2009
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

68 results on '"Aurélie Du Thanh"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources